PACIFIC-AMI
Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of the oral FXIa inhibitor BAY 2433334 in patients following ACS
- Stage
- klaar
- Medicine
- FXIa inhibitor BAY 2433334
- Population
- ASCVD
- Phase
- II
- First Patient In
- 5 August 2020
- Last Patient In
- 15 July 2021
- Last Patient Last Visit
- 10 February 2022
Study Director
dr. R.S. Hermanides
Cardioloog
Office Contact
